Search

everythinglearnresearchcommunity

for

Search:↓

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Abrocitinib may effectively treat stubborn alopecia universalis.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

A new cream, DHMEQ, reduces allergic skin inflammation effectively.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

The new gel effectively treats psoriasis with minimal side effects.

Dupilumab helped a 4-year-old grow hair back after another treatment failed.

Methylprednisolone helps skin cells stick together better in pemphigus vulgaris.

Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.

AI-09 is safe, effective, and reduces wrinkles for up to 6 months.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

A woman with alopecia regrew her hair after taking a higher dose of tocilizumab.

Paeonol-loaded gels may help reduce inflammation and skin damage in atopic dermatitis.

New targeted therapies for psoriasis show promise but face challenges like side effects and treatment resistance.

Adalimumab was safe but mostly ineffective for severe alopecia areata.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Stopping the medication infliximab and starting new treatments helped a woman's hair grow back and improved her scalp condition.

Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.

Ustekinumab treatment didn't prevent frontal fibrosing alopecia.

Blocking EGFR in skin cells doesn't majorly increase inflammation markers.

A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.